
    
      This is an international, multicentre, parallel group, event-driven, randomized,
      double-blind, placebo-controlled study in patients with chronic heart failure with reduced
      ejection fraction (HFrEF), evaluating the effect of dapagliflozin versus placebo, given once
      daily in addition to background regional standard of care therapy, for the prevention of
      cardiovascular (CV) death or reduction of heart failure (HF) events.
    
  